Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @AndrewE_Dunn
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AndrewE_Dunn
-
Prikvačeni tweet
The fabled PERSONAL NEWS tweet: Today’s my first day as Business Insider’s pharma and biotech reporter! So excited to keep covering the industry as part of BI’s healthcare team — get in touch, everyone.
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Simple — yet stunning — graphic to see. # of confirmed cases of coronavirus in China, per daily situation reports from WHO. Just under 25,000 cases if you add suspected cases in China.pic.twitter.com/yHLc9NwMZ0
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Andrew Dunn proslijedio/la je Tweet
This week's Dispensed is out! In it: - So much on
$ONEM + the primary care biz overall -@AndrewE_Dunn 's insights from biotech/pharma earnings - my deep-dive on$WBA's partnership strategy Subscribe!https://www.businessinsider.com/dispensed-weekly-healthcare-newsletter-january-31-2020-1 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Just published in The Lancet: a new model by U. of Hong Kong researchers says 75,800 individuals in Wuhan may have been infected w/ coronavirus as of Jan. 25. Also says multiple major Chinese cities may have enough cases for local epidemics. https://www.thelancet.com/pb-assets/Lancet/pdfs/S0140673620302609.pdf …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Andrew Dunn proslijedio/la je Tweet
Here we go: One Medical is set to start trading today after raising $245 million in its IPOhttps://www.businessinsider.com/one-medical-goes-public-stock-price-in-digital-health-ipo-2020-1 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Andrew Dunn proslijedio/la je Tweet
#Coronavirus: Stunning new numbers. Running totals - 9,171 confirmed cases worldwide vs 7,711 China cases yesterday; 213 deaths vs 130 yesterday. More than 12,000 suspected cases. 1,476 in serious or critical condition. ALL regions of China are reporting cases. h/t@V2019NPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amgen's Herceptin and Avastin biosimilars posted $79M each in US sales for Q4. The co. says that represents 15% and 17% of the market, respectively
$AMGNPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amgen says it will exceed $1 billion in biosimilar sales for 2020. In 2019, they launched their first 2 in the US for Herceptin and Avastin
$AMGN Q4 45-slide presentation now live here: http://investors.amgen.com/static-files/a6cdc50f-ef64-4967-befc-b430ba7efe0b …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Quite the IPO for Black Diamond Therapeutics — stock priced closed just under $40 today. Initially priced at $19.
$BDTXHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
While dodging most of today's questions on aducanumab, Biogen execs did give some updates Read more here on the re-dosing study and future combination therapies in Alzheimer's for
$BIIB:https://www.businessinsider.com/biogen-alzheimers-drug-aducanumab-fda-filing-update-what-we-know-2020-1 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Fascinating way to visually show the development timeline of drugs here, and how different policies affect the rewards
https://twitter.com/peterbachmd/status/1222646669239517187 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sandrock says Biogen built its Alz. pipeline with combination therapies in mind. He says the most obvious Alzheimer's combination to try is adding an anti-tau to aducanumab
$BIIBPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The re-dosing study will be single arm, so main focus will be safety and tolerability. Sandrock likened it to an open-label extension — but also said they will look at efficacy as best as they can on biomarkers like amyloid.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Biogen's Al Sandrock says the company is running the aducanumab re-dosing study primarily for humanitarian reasons. "We felt we owed something to them [the patients]. Many of them expressed a desire to the investigators that they wanted the drug," he said
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Biogen has also filed protocol to the FDA to start a re-dosing study of aducanumab. Now working with clinical sites and ethics committee to start running trial. Will be open to people previously enrolled in an aducanumab trial to start receiving the drug again.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$BIIB CEO Michel Vounatsos on current status of aducanumab filing: "We are actively engaging with the FDA as well as regulators in Europe and Japan, and we look forward to completing a regulatory filing in the US as soon as possible."Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Rubius has dosed the first patient in its PKU Phase 1 study. Reminder the timeline on this, maintained well into late 2019, was an early readout by end of last year. The biotech now isn't putting out a timeline on initial data.
$RUBY PR:https://ir.rubiustx.com/news-releases/news-release-details/rubius-therapeutics-announces-first-patient-dosed-phase-1b-trial …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Novartis just laid out the playbook for making its $2.1 million gene therapy treatment a blockbuster. Here are the next steps:https://www.businessinsider.com/novartis-zolgensma-spinal-muscular-atrophy-gene-therapy-sales-2020-1 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The largest case study yet of coronavirus just published in The Lancet — 99 patients. About half were exposed to the Huanan seafood market -- 46 of the 99 worked at the market as managers or salespeople. Study here:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.